Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$30.34M$30.34Mderived+43.0% vs Q4 2024 Net Income-$67.15M-$67.15MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$57,636,000N/M Operating Cash Flowderived-$52,290,000N/M Free Cash Flowderived-$52,798,000N/M Margins · derivedOperating margin-190.0%+52.2 pt vs Q4 2024
Net margin-221.3%+19.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 5, 2026 · 64 d after period end